{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:56:20Z","timestamp":1791608180068,"version":"4.3.4"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To assess the efficacy and safety of suprachoroidal triamcinolone acetonide in the management of noninfectious cystoid macular edema of various etiologies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Retrospective observational study of 61 eyes of 56 patients with noninfectious cystoid macular edema who received suprachoroidal triamcinolone acetonide injection. Primary outcomes were treatment response, central subfield thickness, visual acuity, and intraocular pressure at baseline, 1 month, and 3 months after injection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Cystoid macular edema etiology included postoperative, uveitis, diabetes mellitus, and retinal vein occlusion. Complete resolution of cystoid macular edema occurred in 34 eyes (58.6%) at 1 month and 23 eyes (50.0%) at 3 months. Median central subfield thickness improved from 430.0\n                      <jats:italic toggle=\"yes\">\u00b5<\/jats:italic>\n                      m (IQR, 366.0\u2013547.5) to 297.0\n                      <jats:italic toggle=\"yes\">\u00b5<\/jats:italic>\n                      m (IQR, 277.0\u2013392.0) at 1 month (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001) and 326.5\n                      <jats:italic toggle=\"yes\">\u00b5<\/jats:italic>\n                      m (IQR, 263.9\u2013380.6) at 3 months (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). Visual acuity improved from logarithm of the minimal angle of resolution 0.60 (IQR, 0.40\u20130.88) [20\/80] at baseline to 0.48 (IQR, 0.30\u20130.70) [20\/60] at 1 month (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.002) and logarithm of the minimal angle of resolution 0.44 (IQR, 0.18\u20130.88) [20\/60] at 3 months (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.019). Significant intraocular pressure elevation was noted in seven eyes (11.5%) overall, with no occurrences of infection, cataract progression, or suprachoroidal hemorrhage.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Suprachoroidal triamcinolone acetonide demonstrated significant anatomical and functional improvements in eyes with noninfectious cystoid macular edema and a reassuring side effect profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/iae.0000000000004688","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T19:00:53Z","timestamp":1758567653000},"page":"240-248","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["EFFICACY AND SAFETY OF SUPRACHOROIDAL TRIAMCINOLONE ACETONIDE IN MIXED ETIOLOGY NONINFECTIOUS CYSTOID MACULAR EDEMA"],"prefix":"10.1097","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6991-6867","authenticated-orcid":false,"given":"Marcus","family":"Yamamoto","sequence":"first","affiliation":[{"name":"Jules Stein Eye Institute, Department of Ophthalmology, UCLA, Los Angeles, CA"},{"name":"John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Hanson","sequence":"additional","affiliation":[{"name":"Jules Stein Eye Institute, Department of Ophthalmology, UCLA, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro I.","family":"Marin","sequence":"additional","affiliation":[{"name":"Jules Stein Eye Institute, Department of Ophthalmology, UCLA, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley","family":"Gundlach","sequence":"additional","affiliation":[{"name":"Jules Stein Eye Institute, Department of Ophthalmology, UCLA, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Au","sequence":"additional","affiliation":[{"name":"Jules Stein Eye Institute, Department of Ophthalmology, UCLA, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirk","family":"Hou","sequence":"additional","affiliation":[{"name":"Jules Stein Eye Institute, Department of Ophthalmology, UCLA, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Hosseini","sequence":"additional","affiliation":[{"name":"Jules Stein Eye Institute, Department of Ophthalmology, UCLA, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz","family":"Pettenkofer","sequence":"additional","affiliation":[{"name":"Jules Stein Eye Institute, Department of Ophthalmology, UCLA, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"McCannel","sequence":"additional","affiliation":[{"name":"Jules Stein Eye Institute, Department of Ophthalmology, UCLA, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeep","family":"Prasad","sequence":"additional","affiliation":[{"name":"Jules Stein Eye Institute, Department of Ophthalmology, UCLA, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy","family":"Chen","sequence":"additional","affiliation":[{"name":"Jules Stein Eye Institute, Department of Ophthalmology, UCLA, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund","family":"Tsui","sequence":"additional","affiliation":[{"name":"Jules Stein Eye Institute, Department of Ophthalmology, UCLA, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irena","family":"Tsui","sequence":"additional","affiliation":[{"name":"Jules Stein Eye Institute, Department of Ophthalmology, UCLA, Los Angeles, CA"},{"name":"VA Greater Los Angeles Healthcare System, Department of Ophthalmology, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260120","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1080\/17425247.2021.1867532","article-title":"Biomechanics of suprachoroidal drug delivery: from benchtop to clinical investigation in ocular therapies","volume":"18","author":"Hancock","year":"2021","journal-title":"Expert Opin Drug Deliv"},{"key":"R2-20260120","doi-asserted-by":"crossref","first-page":"967","DOI":"10.3390\/pharmaceutics13070967","article-title":"Drug delivery via the suprachoroidal space for the treatment of retinal diseases","volume":"13","author":"Naftali Ben Haim","year":"2021","journal-title":"Pharmaceutics"},{"key":"R3-20260120","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s11095-010-0271-y","article-title":"Suprachoroidal drug delivery to the back of the eye using hollow microneedles","volume":"28","author":"Patel","year":"2011","journal-title":"Pharm Res"},{"key":"R4-20260120","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1167\/iovs.12-9872","article-title":"Targeted administration into the suprachoroidal space using a microneedle for drug delivery to the posterior segment of the eye","volume":"53","author":"Patel","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R5-20260120","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1167\/iovs.15-16597","article-title":"Real-time monitoring of suprachoroidal space (SCS) following SCS injection using ultra-high resolution optical coherence tomography in Guinea pig eyes","volume":"56","author":"Gu","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R6-20260120","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.3390\/jcm10184133","article-title":"Update on the management of uveitic macular edema","volume":"10","author":"Teper","year":"2021","journal-title":"J Clin Med"},{"key":"R7-20260120","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/ceo.13702","article-title":"Local delivery of corticosteroids in clinical ophthalmology: a review","volume":"48","author":"Fung","year":"2020","journal-title":"Clin Exp Ophthalmol"},{"key":"R8-20260120","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3390\/pharmaceutics14010134","article-title":"Topical drug delivery to the posterior segment of the eye","volume":"14","author":"L\u00f6scher","year":"2022","journal-title":"Pharmaceutics"},{"key":"R9-20260120","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0008-4182(05)80119-X","article-title":"Complications of intravitreal injection of triamcinolone acetonide","volume":"40","author":"Ozkiri\u015f","year":"2005","journal-title":"Can J Ophthalmol"},{"key":"R10-20260120","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.ophtha.2023.04.011","article-title":"Intravitreal therapy for uveitic macular edema-ranibizumab versus methotrexate versus the dexamethasone implant: the MERIT trial results","volume":"130","author":"Acharya","year":"2023","journal-title":"Ophthalmology"},{"key":"R11-20260120","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ophtha.2018.08.021","article-title":"Periocular triamcinolone vs. intravitreal triamcinolone vs. intravitreal dexamethasone implant for the treatment of uveitic macular edema: the PeriOcular vs. INTravitreal corticosteroids for uveitic macular edema (POINT) trial","volume":"126","author":"Thorne","year":"2019","journal-title":"Ophthalmology"},{"key":"R12-20260120","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1080\/09273948.2023.2262015","article-title":"Safety and efficacy of CLS-TA by anatomic location of inflammation: results from the phase 3 PEACHTREE clinical trial","volume":"32","author":"Shah","year":"2024","journal-title":"Ocul Immunol Inflamm"},{"key":"R13-20260120","first-page":"1139","article-title":"Extension study of the safety and efficacy of CLS-TA for treatment of macular oedema associated with non-infectious uveitis (MAGNOLIA)","volume":"106","author":"Khurana","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"R14-20260120","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"R16-20260120","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3928\/1081-597X-19970701-16","article-title":"Proper method for calculating average visual acuity","volume":"13","author":"Holladay","year":"1997","journal-title":"J refractive Surg"},{"key":"R17-20260120","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1097\/IAE.0000000000004132","article-title":"Suprachoroidal triamcinolone acetonide for refractory postoperative cystoid macular edema","volume":"44","author":"Momenaei","year":"2024","journal-title":"Retina"},{"key":"R18-20260120","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ajo.2024.11.022","article-title":"Suprachoroidal triamcinolone acetonide for noninfectious uveitis: real-world impact on clinical outcomes","volume":"271","author":"Panse","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"R19-20260120","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1007\/s00417-023-06163-5","article-title":"Incidence and treatment approach of intraocular pressure elevation after various types of local steroids for retinal diseases","volume":"261","author":"Wykrota","year":"2023","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R20-20260120","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jcjo.2020.06.021","article-title":"Ocular hypertension following 40 mg sub-tenon triamcinolone versus 0.7 mg dexamethasone implant versus 2 mg intravitreal triamcinolone","volume":"55","author":"Kuley","year":"2020","journal-title":"Can J Ophthalmol"},{"key":"R21-20260120","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1136\/bjo.87.1.24","article-title":"Intraocular pressure after intravitreal injection of triamcinolone acetonide","volume":"87","author":"Jonas","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"R22-20260120","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/j.ophtha.2014.04.024","article-title":"Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema","volume":"121","author":"Boyer","year":"2014","journal-title":"Ophthalmology"},{"key":"R23-20260120","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1097\/IAE.0000000000003080","article-title":"Long-term incidence and risk factors of ocular hypertension following dexamethasone-implant injections: the SAFODEX-2 study","volume":"41","author":"Rezkallah","year":"2021","journal-title":"Retina"},{"key":"R24-20260120","doi-asserted-by":"crossref","first-page":"585","DOI":"10.4103\/ijo.IJO_684_21","article-title":"Secondary glaucoma after intravitreal dexamethasone implant (ozurdex) injection in patients with retinal disorder: a retrospective study","volume":"70","author":"Sweta","year":"2022","journal-title":"Indian J Ophthalmol"},{"key":"R25-20260120","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/01.ijg.0000151880.22479.d7","article-title":"Intravitreal triamcinolone acetonide and secondary ocular hypertension","volume":"14","author":"Jonas","year":"2005","journal-title":"J Glaucoma"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004688","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T17:00:37Z","timestamp":1768928437000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004688","relation":{},"ISSN":["0275-004X","1539-2864"],"issn-type":[{"value":"0275-004X","type":"print"},{"value":"1539-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]}}}